How Will Biologics Fit Into Healthcare Reform?: With so many variables, it's hard to predict what kind of market will exist for biologics and other specialty drugs in 2014. Current trends may provide some insight.

Biotechnology healthcare Pub Date : 2011-01-01
Michael D Dalzell
{"title":"How Will Biologics Fit Into Healthcare Reform?: With so many variables, it's hard to predict what kind of market will exist for biologics and other specialty drugs in 2014. Current trends may provide some insight.","authors":"Michael D Dalzell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Institute of Medicine says that health benefit packages should be limited by cost, not services, but doesn't address the coverage of biologics. Employers, meanwhile, are thinking about limiting access to high-priced drugs. Yet, industry reports say that biologics are set to dominate drug spend by 2015. Are we moving toward healthcare rationing?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 4","pages":"6-10"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278131/pdf/bh0804006.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The Institute of Medicine says that health benefit packages should be limited by cost, not services, but doesn't address the coverage of biologics. Employers, meanwhile, are thinking about limiting access to high-priced drugs. Yet, industry reports say that biologics are set to dominate drug spend by 2015. Are we moving toward healthcare rationing?

生物制剂如何适应医疗改革?由于变数太多,很难预测2014年生物制剂和其他特殊药品的市场将会是怎样的。当前的趋势或许能提供一些启示。
美国医学研究所(Institute of Medicine)表示,健康福利计划应该受成本限制,而不是服务,但它并没有解决生物制剂的覆盖问题。与此同时,雇主们正在考虑限制获得高价药品的途径。然而,行业报告称,到2015年,生物制剂将主导药品支出。我们正在走向医疗配给吗?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信